1. Home
  2. SONM vs TNXP Comparison

SONM vs TNXP Comparison

Compare SONM & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonim Technologies Inc.

SONM

Sonim Technologies Inc.

HOLD

Current Price

$3.30

Market Cap

7.4M

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$16.26

Market Cap

201.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONM
TNXP
Founded
1999
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4M
201.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
SONM
TNXP
Price
$3.30
$16.26
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$70.00
AVG Volume (30 Days)
40.7K
552.0K
Earning Date
10-31-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,109,000.00
$10,299,000.00
Revenue This Year
$127.68
$2.96
Revenue Next Year
N/A
$750.19
P/E Ratio
N/A
N/A
Revenue Growth
4.17
N/A
52 Week Low
$3.71
$6.76
52 Week High
$114.84
$69.97

Technical Indicators

Market Signals
Indicator
SONM
TNXP
Relative Strength Index (RSI) 27.93 37.99
Support Level $4.93 $17.71
Resistance Level $6.10 $19.35
Average True Range (ATR) 0.57 1.07
MACD -0.21 -0.21
Stochastic Oscillator 2.33 5.40

Price Performance

Historical Comparison
SONM
TNXP

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: